Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a clinical-stage biotechnology company focused on therapies for immune-mediated and metabolic diseases, with a particular emphasis on ophthalmology and rare retinal conditions. News about Aldeyra often centers on the progress of its RASP (reactive aldehyde species) modulator platform and its late-stage product candidates reproxalap and ADX-2191.
Investors following ALDX news can expect regular updates on regulatory milestones, such as the U.S. Food and Drug Administration’s review of the New Drug Application for topical ocular reproxalap in dry eye disease, extensions of Prescription Drug User Fee Act (PDUFA) target action dates, and feedback on proposed labeling. Aldeyra also reports on orphan drug and fast track designations from the FDA and the European Medicines Agency for ADX-2191 in primary vitreoretinal lymphoma, retinitis pigmentosa, and related inherited retinal dystrophies.
The company’s news flow includes clinical trial readouts and pipeline updates, such as Phase 2 data for ADX-629 in alcohol-associated hepatitis, preclinical results for ADX-248 in models of central nervous system diseases associated with inflammation, and decisions to prioritize next-generation RASP modulators ADX-248 and ADX-246. Aldeyra also issues releases about Special Protocol Assessment agreements, manufacturing inspections and outcomes, and participation in healthcare and ophthalmology conferences and research and development webcasts.
This ALDX news page aggregates these company communications so readers can track developments in Aldeyra’s RASP platform, ophthalmic programs, and broader immune-mediated disease pipeline over time. For investors and observers, the news stream provides context on clinical progress, regulatory interactions, and strategic pipeline decisions that shape the company’s future prospects.
Aldeyra Therapeutics (NASDAQ: ALDX) announced positive results from its crossover clinical trial of the investigational drug reproxalap for dry eye disease. The study achieved primary endpoints, demonstrating statistical superiority over a vehicle for both ocular redness (P=0.0004) and the Schirmer test (P=0.0005). Secondary endpoints also showed significant improvements in dryness, discomfort, grittiness, stinging, burning, and itching symptoms. No safety issues were reported, and the FDA meeting for a New Drug Application is scheduled for Q3 2022, with submission plans for reproxalap data following.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will conduct a webcast and conference call on July 12, 2022, at 8:00 a.m. ET to present top-line results from a crossover clinical trial of reproxalap, an investigational treatment for dry eye disease. The event will be accessible via dial-in or through a live audio webcast on Aldeyra's website. The trial aims to provide insights on the efficacy of reproxalap, which is in late-stage trials targeting immune-mediated diseases. Further details and archives will be available on their website.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) announced that Dr. Todd C. Brady, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 10, 2022, at 9:30 a.m. ET. The event will include a conversation with Dr. Kelly Shi, a Senior Research Analyst in Biotechnology. Investors can access the live webcast through Aldeyra's website, with a video replay available for 90 days afterwards. Aldeyra is focused on innovative therapies for immune-mediated diseases, including its lead candidates, reproxalap and ADX-629.
Aldeyra Therapeutics (ALDX) announced its achievement of the primary endpoint in the Phase 3 TRANQUILITY-2 clinical trial for reproxalap, a treatment for dry eye disease. The drug demonstrated statistical superiority in the Schirmer test (p=0.0001) and responder proportions (p0.0001) after a single dose. The company plans to submit a New Drug Application (NDA) encompassing results from five controlled trials, potentially representing the most comprehensive submission for dry eye disease. A Pre-NDA meeting with the FDA is anticipated in Q3 2022, with results from an ongoing safety trial expected soon.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will host a webcast and conference call on June 8, 2022, at 8:00 a.m. ET to discuss top-line results from its Phase 3 TRANQUILITY-2 Trial of reproxalap in treating dry eye disease. Interested participants can access the call via dial-in numbers or through a live audio webcast on Aldeyra's website. Following the event, a recording will be available on the site for 90 days. Aldeyra is focused on innovative therapies targeting immune-mediated diseases.
Aldeyra Therapeutics (NASDAQ: ALDX) announced Schirmer test designation as the primary endpoint in its Phase 3 TRANQUILITY-2 trial for reproxalap, targeting dry eye disease. This decision follows favorable post-hoc analyses from previous trials, indicating reproxalap’s statistically significant reduction in ocular redness. The company plans to use these results to support a New Drug Application (NDA) submission, pending ongoing safety trials. Results from TRANQUILITY-2 are expected in Q2 2022, highlighting the unmet need for quicker, non-steroidal treatment options in dry eye disease.
Aldeyra Therapeutics, a biotechnology company focused on immune-mediated diseases, announced that President and CEO Todd C. Brady will speak at the H.C. Wainwright Global Investment Conference. The fireside chat, featuring Vice President of Equity Research Matthew Caufield, will be available on demand starting 7:00 a.m. ET on May 24, 2022. Interested viewers can access the event through the Investors & Media section on Aldeyra's website, which will be archived for 90 days. Aldeyra's leading products include reproxalap and ADX-629, targeting immune-inflammation.
Aldeyra Therapeutics (ALDX) announced positive findings from a post-hoc analysis of the Phase 3 TRANQUILITY trial for reproxalap, indicating statistical superiority (p=0.020) in reducing ocular redness, the primary endpoint. This follows a similar confirmation in the Phase 2 trial (p=0.003). Aldeyra plans to engage with the FDA, including ocular redness as an objective sign in its upcoming New Drug Application (NDA) expected mid-2022, contingent on discussions and outcomes from the ongoing TRANQUILITY-2 trial.
Aldeyra Therapeutics (Nasdaq: ALDX) reported its financial results for Q1 2022, with cash holdings of $216.9 million, expected to cover operations through 2023. The company completed enrollment for the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease, with results anticipated in Q2 2022. Positive top-line data from Phase 2 trials of ADX-629 were also announced, leading to new indications in ethanol toxicity and chronic cough. Despite a net loss of $16.8 million, up from $11.3 million year-over-year, Aldeyra continues to progress in clinical trials across various indications.
Aldeyra Therapeutics (NASDAQ: ALDX) will be represented by Kelly Mizer, Vice President, at the MOD Live! 2022 meeting in Nashville, Tennessee, from May 5-7, 2022. The event focuses on innovative therapies in optometry, particularly in the session titled 'The Future of Optometry – Pipeline Game Changers'. Mizer will provide updates on reproxalap, an investigational drug in Phase 3 trials aimed at treating dry eye disease and allergic conjunctivitis.
Aldeyra specializes in therapies for immune-mediated diseases, with a focus on RASP modulators.